Please assess the completion status of the following clinical trial:

Trial Title: Tezosentan in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~1. Signed informed consent prior to initiation of any study-mandated procedure~2. Male and female patients 18 years of age or older~3. Patients with PAH according to one of the following subgroups of the Dana Point Classification Group 1:~   * Idiopathic, or~  * Heritable, or~  * Associated with connective tissue disease~4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of study mandated procedures):~   * Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and~  * Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and~  * Pulmonary capillary wedge pressure ≤ 15 mmHg~5. Modified NYHA functional class II-III~6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days prior to Visit 1.~Exclusion Criteria :~1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups not covered by inclusion criterion No. 3~2. Patients with sitting SBP \< 100 mmHg~3. Patients with sitting DBP \< 60 mmHg~4. Patients with body weight \< 50 kg (110 lbs)~5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or alkaline phosphatase \> 3 times upper limit)~6. Patients with clinically significant chronic renal insufficiency (serum creatinine \>2.5mg/dL / 221 µmol/L)~7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)~8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g., treprostinil, iloprost and beraprost) within 28 days of Visit 1~9. Patients who have received any investigational drugs within 28 days of Visit 1~10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit 1~11. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with the study~12. Life expectancy less than 12 months~13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum test at Screening and urine test on Visit 1 and 2) or females who are not using a reliable method of birth control (failure rate less than 1% per year) during the study and for at least one month after last administration of study drug~14. Known hypersensitivity to any of the excipients of the drug formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Placebo at visit 1, tezosentan at visit 2
- 2 (Type: EXPERIMENTAL): Tezosentan at visit 1, placebo at visit 2

Based on this trial design, predict the completion outcome and termination type (if applicable).